scemblix
(asciminib)Novartis Pharmaceuticals Corporation
Usage: SCEMBLIX is indicated for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, previously treated Ph+ CML in chronic phase, and Ph+ CML in chronic phase with the T315I mutation. Continued approval is contingent on further clinical trials.